文献速递糖尿病

动脉粥样硬化性心血管疾病合并2型糖尿病患者中SGLT2抑制剂与GLP-1受体激动剂的使用率及其机构层面差异:来自退伍军人事务部的洞察

Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
PubMed 文献 · Diabetes Care · 2022-01-01

该研究利用2020年1月1日至2020年12月31日全国退伍军人事务部医疗系统数据,纳入已确诊动脉粥样硬化性心血管疾病(ASCVD)和2型糖尿病(T2DM)的患者,评估SGLT2抑制剂(SGLT2i)和GLP-1受体激动剂(GLP-1 RA)的使用率及机构层面差异。在130家机构的537,980例患者中,11.2%使用SGLT2i,8.0%使用GLP-1 RA;机构层面使用率存在显著差异,校正后中位率比(MRR)分别为1.55(95%CI 1.46-1.63)和1.78(95%CI 1.65-1.90)。结论认为这些药物使用率低且机构间差异显著,提示有机会优化其使用以预防未来不良心血管事件。

要点

  • 在537,980例ASCVD合并T2DM患者中,SGLT2i使用率为11.2%,GLP-1 RA使用率为8.0%。
  • 机构层面SGLT2i使用率中位数(第10-90百分位)为14.92%(9.31-22.50),GLP-1 RA为10.88%(4.44-17.07)。
  • 校正后机构间使用差异显著:SGLT2i的MRR为1.55(95%CI 1.46-1.63),GLP-1 RA的MRR为1.78(95%CI 1.65-1.90)。

核心结论

  • 在符合条件的ASCVD合并T2DM患者中,SGLT2i和GLP-1 RA的总体使用率低,且使用存在显著更高的机构层面残余差异。
  • 研究结果提示有机会优化这些药物的使用以预防患者未来不良心血管事件。

研究设计与样本

  • 研究使用2020年1月1日至2020年12月31日全国退伍军人事务部(VA)医疗系统数据集,纳入已确诊ASCVD和T2DM的患者。
  • 共纳入537,980例患者,分布于130家VA机构。
  • 评估SGLT2i和GLP-1 RA的使用率及机构层面差异,机构层面差异采用中位率比(MRR)计算。

主要发现

  • 在537,980例ASCVD合并T2DM患者中,11.2%接受SGLT2i,8.0%接受GLP-1 RA。
  • 接受这些心脏保护性降糖药物的患者平均更年轻,非西班牙裔白人比例更高。
  • 机构层面SGLT2i使用率中位数(第10-90百分位)为14.92%(9.31-22.50),GLP-1 RA为10.88%(4.44-17.07)。
  • SGLT2i使用的机构层面差异:未校正MRR为1.41(95%CI 1.35-1.47),校正后MRR为1.55(95%CI 1.46-1.63)。
  • GLP-1 RA使用的机构层面差异:未校正MRR为1.34(95%CI 1.29-1.38),校正后MRR为1.78(95%CI 1.65-1.90)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is mounting evidence regarding the cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) among patients with atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2DM). There is paucity of data assessing real-world practice patterns for these drug classes. We aimed to assess utilization rates of these drug classes and facility-level variation in their use. RESEARCH DESIGN AND METHODS: We used the nationwide Veterans Affairs (VA) health care system data set from 1 January 2020 to 31 December 2020 and included patients with established ASCVD and T2DM. Among these patients, we assessed the use of SGLT2i and GLP-1 RA and the facility-level variation in their use. Facility-level variation was computed using median rate ratios (MRR), a measure of likelihood that two random facilities differ in use of SGLT2i and GLP-1 RA in patients with ASCVD and T2DM. RESULTS: Among 537,980 patients with ASCVD and T2DM across 130 VA facilities, 11.2% of patients received an SGLT2i while 8.0% of patients received a GLP-1 RA. Patients receiving these cardioprotective glucose-lowering drug classes were on average younger and had a higher proportion of non-Hispanic Whites. Overall, median (10th-90th percentile) facility-level rates were 14.92% (9.31-22.50) for SGLT2i and 10.88% (4.44-17.07) for GLP-1 RA. There was significant facility-level variation among SGLT2i use-MRRunadjusted: 1.41 (95% CI 1.35-1.47) and MRRadjusted: 1.55 (95% CI 1.46 -1.63). Similar facility-level variation was observed for use of GLP-1 RA-MRRunadjusted: 1.34 (95% CI 1.29-1.38) and MRRadjusted: 1.78 (95% CI 1.65-1.90). CONCLUSIONS: Overall utilization rates of SGLT2i and GLP-1 RA among eligible patients are low, with significantly higher residual facility-level variation in the use of these drug classes. Our results suggest opportunities to optimize their use to prevent future adverse cardiovascular events among these patients.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mahtta D, Ramsey DJ, Lee MT, et al. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022. PMID: 35015080. doi:10.2337/dc21-1815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。